PF-07265028 進行性または転移性固形腫瘍における単剤およびササンリマブとの併用

基本情報

NCT ID

NCT05233436

ステータス

中止

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

21

治験依頼者名

Pfizer

概要

The purpose of this study is to assess the safety and effects of PF-07265028 as monotherapy and in combination with sasanlimab. The study aims to identify the maximum tolerated dose (MTD) of PF-07265028 as monotherapy; evaluate the clinical activity of monotherapy and combination; and select the recommended dose of PF-07265028 monotherapy and in combination for potential further studies and development. The study contains 2 parts, Dose Escalation (Part 1) to determine the recommended dose of PF-07265028 as single agent and in combination, followed by Dose Expansion (Part 2) in selected tumor types at the recommended dose. It is expected that most participants will take part in this study for up to 1 year with six on-site visits in the first month and then at least twice every subsequent month while they are on treatment.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)